| Outcome Measures: |
Primary: Change in Baseline in Glycosylated hemoglobin., Weeks: 4, 8, 12, 16, 20 and Final Visit. | Secondary: Change in Baseline in Glycosylated hemoglobin., Weeks: 4, 8, 12, 16, 20 and Final Visit.|Change in Baseline in Fasting Plasma Glucose., Weeks: 2, 4, 8, 12, 16, 20 and Final Visit.|Change in Baseline in Serum insulin., Weeks: 4, 12, 16, 20 and Final Visit.|Change in Baseline in C-peptide., Weeks: 4, 12, 16, 20 and Final Visit.|Change in Baseline in Lipids (triglycerides, total cholesterol, high-density lipoprotein, low-density lipoprotein, very-low-density lipoprotein)., Weeks: 12, 16, 20 and Final Visit.|Change in Baseline in Lipids (low-density lipoprotein fractionation)., Weeks: 12, 16, 20 and Final Visit.|Change in Baseline in Apolipoproteins Al and B100., Final Visit.|Change in Baseline in Free fatty acids., Weeks: 12, 16, 20 and Final Visit.|Markers of thrombosis (plasminogen activator inhibitor-i)., Weeks: 4, 12, 16, 20 and Final Visit.|Markers of thrombosis (fibrinogen)., Weeks: 4, 12, 16, 20 and Final Visit.|Markers of inflammation (interleukin-6)., Weeks: 4, 12, 16, 20 and Final Visit.|Markers of inflammation (C-reactive protein)., Weeks: 4, 12, 16, 20 and Final Visit.|Urinary albumin/creatinine ratio., Weeks: 12, 16, 20 and Final Visit.
|
